DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Clinician Decision Support Algorithm for Chemotherapy-Induced Peripheral Neuropathy

Not Applicable

Completed

Conditions: Cancer
Chemotherapy-induced Peripheral Neuropathy

Interventions: Behavioral: CIPN Assessment and Management Algorithm

First Posted Date: 2018-05-02

Last Posted Date: 2022-03-16

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 226

Registration Number: NCT03514680

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Role of Contrast Enhanced Spectral Mammography to Predict Upgrade Rates of Biopsy Proven Atypical Ductal Hyperplasia

Not Applicable

Terminated

Conditions: Atypical Ductal Hyperplasia

Interventions: Device: Contrast enhanced mammography

First Posted Date: 2018-04-23

Last Posted Date: 2020-02-11

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 5

Registration Number: NCT03505372

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: LY3300054
Drug: Prexasertib

First Posted Date: 2018-04-12

Last Posted Date: 2021-04-15

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 17

Registration Number: NCT03495323

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Phase 1

Active, not recruiting

Conditions: Blastic Plasmacytoid Dendritic Cell Neoplasm

Interventions: Drug: Venetoclax

First Posted Date: 2018-04-02

Last Posted Date: 2024-02-13

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 5

Registration Number: NCT03485547

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis

Phase 2

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Atezolizumab
Procedure: Stereotactic radiosurgery (SRS)

First Posted Date: 2018-03-29

Last Posted Date: 2024-08-07

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 6

Registration Number: NCT03483012

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Study of Pancreatic Enzyme Replacement on Completion of Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma

Phase 2

Terminated

Conditions: Pancreatic Cancer

Interventions: Drug: Pancrelipase

First Posted Date: 2018-03-19

Last Posted Date: 2020-08-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 4

Registration Number: NCT03469258

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

MCS110 With BRAF/MEK Inhibition in Patients With Melanoma

Phase 1

Completed

Conditions: Melanoma

Interventions: Drug: MCS110
Drug: Dabrafenib
Drug: Trametinib

First Posted Date: 2018-03-07

Last Posted Date: 2024-07-31

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 6

Registration Number: NCT03455764

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Understanding Barriers to Initiation and Adherence to Endocrine Therapy in Young Breast Cancer Survivors of Diverse Backgrounds

Completed

Conditions: Breast Cancer

Interventions: Other: Phone interview

First Posted Date: 2018-02-27

Last Posted Date: 2021-06-11

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 17

Registration Number: NCT03447886

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC

Phase 2

Terminated

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Ipilimumab
Drug: Nivolumab

First Posted Date: 2018-02-07

Last Posted Date: 2024-08-22

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 5

Registration Number: NCT03425331

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Study of Radiation Fractionation on Patient Outcomes After Breast REConstruction (FABREC) for Invasive Breast Carcinoma

Not Applicable

Active, not recruiting

Conditions: Breast Cancer

Interventions: Radiation: Radiation Therapy

First Posted Date: 2018-02-05

Last Posted Date: 2024-11-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 400

Registration Number: NCT03422003

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Stanford University Medical Center, Stanford, California, United States

and more 12 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy